Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Janssen-Cilag International NV
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 5 ans
A Randomized, Multicenter, Double-Blind, Active-Controlled, Flexible-Dose, Parallel-Group Study of the Efficacy and Safety of Prolonged Release Paliperidone for the Treatment of Symptoms of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age
Evaluate the efficacy of paliperidone PR relative to aripiprazole in the treatment of symptoms of schizophrenia in adolescent subjects (aged 12 to 17 years of age, inclusive) at the Week 8 endpoint as...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
MAJ Il y a 5 ans
A Randomised, double blind, Placebo controlled, double dummy, parallel group, multicentre, dose ranging study in subjects with T2DM to evaluate the efficacy, safety, and tolerability of orally administered SGLT2 inhibitor JNJ-28431754 with Sitagliptin as a reference arm
The primary objective of this dose-ranging study is to evaluate the effects of JNJ-28431754 as compared with placebo on the change in hemoglobin A1c (A1C) from baseline to Week 12 in subjects with T2D...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 5 ans
A 3-Year Follow-up Study in Subjects previously treated with Odalasvir and AL-335 With or Without Simeprevir for Hepatitis C Virus (HCV) Infection. Estudio de 3 años de seguimiento en sujetos tratados con anterioridad con odalasvir y AL-335 con o sin simeprevir para la infección por el virus de la hepatitis C (VHC)
To evaluate the durability of SVR in subjects who achieved SVR at last post-therapy visit of parent study (LPVPS). Evaluar la durabilidad de la RVS en sujetos que han logrado la RVS en la última...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 5 ans
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression
To assess the efficacy and dose response of intranasal esketamine compared with placebo in improving depressive symptoms in subjects with TRD
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 5 ans
A Study of Abiraterone Acetate and Prednisone with Androgen Deprivation Therapy (ADT) versus ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic (spread of cancer cells from one part of the body to another) Prostate Cancer
To determine whether abiraterone acetate in combination with low-dose prednisone and androgen deprivation therapy (ADT) is superior to ADT alone in improving rPFS and OS in subjects with mHNPC with ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 5 ans
A study of multiple different dosages of JNJ-38518168 and placebo in patients with active Rheumatoid Arthritis who are also receiving methotrexate
The primary objective is to assess the efficacy (as measured by the reduction of the signs and symptoms of RA) of JNJ-38518168-ZBQ at doses of 3, 10, and 30 mg/d compared with placebo in subjects wit...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 5 ans
A Study to Evaluate the Safety and Efficacy of the Ustekinumab Induction and Maintenance Therapy in Participants with Moderately to Severely Active Ulcerative Colitis
Induction study: -To evaluate the efficacy of IV ustekinumab in inducing clinical remission in subjects with moderately to severely active ulcerative colitis (UC). -To evaluate the safety of IV uste...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 5 ans
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents with Type 2 Diabetes Mellitus
The primary objective of this study is to evaluate the pharmacokinetics of canagliflozin after multiple oral doses of canagliflozin in children and adolescent subjects with T2DM who are 10 to <18 yea...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 5 ans
A Randomized, Open-Label, Multicenter Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Subjects Previously Treated With Rituximab
The primary objective is to determine the complete response rate (CR+CRu) following treatment with VELCADE in combination with fludarabine (VF) compared with rituximab in combination with fludarabine ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 5 ans
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26 Week Multicenter Study with a 26-Week Extension to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 (Canagliflozin) Compared with Placebo in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Pioglitazone Therapy
• To assess the effect of canagliflozin relative to placebo on hemoglobin A1c (HbA1c) after 26 weeks of treatment • To assess the safety and tolerability of canagliflozin
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
3
4
5
6
7
8
9
10
11
12
Suivant